title: [Regional cytostatic perfusion of the extremities in patients with malignant melanoma and soft tissue sarcoma--therapeutic applications and results].
abstract: 94 patients with malignant melanoma or soft tissue sarcoma of the extremities were submitted to isolated cytostatic limb perfusion. With palliative indication for treatment of malignant melanoma, the 5 year survival rate was 25% after perfusion with methotrexate and 50% after perfusion with melphalan. The adjuvant perfusion showed very good results, too. Furthermore, the authors report on their first experiences in regional cytostatic perfusion of soft tissue sarcoma and bone sarcoma.
authors.affiliation: Chirurgische Klinik und Poliklinik, Martin-Luther-Universität Halle-Wittenberg.
authors.forename: U
authors.initials: U
authors.lastname: Eichfeld
authors.forename: A
authors.initials: A
authors.lastname: Gläser
authors.forename: G
authors.initials: G
authors.lastname: Schneider
authors.forename: J
authors.initials: J
authors.lastname: Kraus
authors.forename: H J
authors.initials: HJ
authors.lastname: Pauer
authors.forename: I
authors.initials: I
authors.lastname: Schwarz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005121:Extremities / Q000601:surgery; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D010166:Palliative Care; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D008558:Melphalan; D008727:Methotrexate